The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Pursuing the leadlikeness concept in pharmaceutical research
Abstract
Lipinski and others, through concepts such as drug-likeness, re-focussed drug discovery back to the principles of medicinal chemistry in the high-throughput era as key to reducing attrition. More recently, the need to go further in defining what makes a good lead has been recognised with the concept of leadlikeness. Leadlikeness implies cut-off values in the physico-chemical profile of chemical libraries such that they have reduced complexity (e.g. MW below <400) and other more restricted properties. We examine these concepts in the context of Virtual (theoretically possible), Tangible (chemically feasible) and Real (physically available) worlds of molecules. In a thought experiment, we take the HTS concept to the extreme: screening an estimated 60 million 'Global Collection' on 5000 targets and realising that perhaps millions of drug candidates might be found that could not possibly be handled in reality. Sampling of the Virtual and Tangible worlds is therefore a necessity. We show that the world of Reals is significantly under-sampled as the MW of compounds increases. This supports the design and screening of 'reduced complexity' (leadlike) compound libraries, preferably with synthetic handles available for rapid chemical iteration and detected as interesting by careful screening or biophysical assays.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
Encyclopedia of Computational Chemistry
(1998) · Wiley eBooks · doi:10.1002/0470845015 · Cited by 2,742
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
Self-citationThe Design of Leadlike Combinatorial Libraries
Teague, S. J., Davis, A. M., Leeson, P. D., & Oprea, T. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19991216)38:24<3743::aid-anie3743>3.0.co;2-u · Cited by 870
Self-citationThe maximal affinity of ligands
Kuntz, I. D., Chen, K., Sharp, K. A., & Kollman, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9997 · Cited by 849
Is There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769
Self-citationCalculating log Poct from structures
Leo, A. J. (1993) · Chemical Reviews · doi:10.1021/cr00020a001 · Cited by 695
Property distribution of drug-related chemical databases*
Oprea, T. I. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008130001697 · Cited by 628
Self-citationCan We Learn To Distinguish between “Drug-like” and “Nondrug-like” Molecules?
Ajay, Walters, W. P., & Murcko, M. A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970666c · Cited by 484
A Scoring Scheme for Discriminating between Drugs and Nondrugs
Sadowski, J., & Kubinyi, H. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9706776 · Cited by 392
Application and Limitations of X‐ray Crystallographic Data in Structure‐Based Ligand and Drug Design
Davis, A. M., Teague, S. J., & Kleywegt, G. J. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200539 · Cited by 387
Nonleadlikeness and leadlikeness in biochemical screening
Rishton, G. M. (2003) · Drug Discovery Today · doi:10.1016/s1359644602025722 · Cited by 381
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Drug research: myths, hype and reality
Kubinyi, H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1156 · Cited by 348
Drugs, leads, and drug-likeness: an analysis of some recently launched drugs
Proudfoot, J. R. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00244-5 · Cited by 252
Roche, O., Schneider, P., Zuegge, J., Guba, W., Kansy, M., Alanine, A., Bleicher, K., Danel, F., Gutknecht, E.-M., Rogers-Evans, M., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010934d · Cited by 248
Horrobin, D. F. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1012 · Cited by 248
Virtual Screening in Drug Discovery
(2005) · CRC Press eBooks · doi:10.1201/9781420028775 · Cited by 235
Current trends in lead discovery: Are we looking for the appropriate properties?
Oprea, T. I. (2002) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1020877402759 · Cited by 193
Self-citationChemoinformatics: What is it and How does it Impact Drug Discovery.
Brown, F. K. (1998) · Annual Reports in Medicinal Chemistry · doi:10.1016/s0065-7743(08)61100-8 · Cited by 180
Innovation in the pharmaceutical industry
Horrobin, D. F. (2000) · Journal of the Royal Society of Medicine · doi:10.1177/014107680009300702 · Cited by 173
Pan, Y., Huang, N., Cho, S., & MacKerell, A. D. (2002) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci020055f · Cited by 162
Tronde, A., Nordén, B. O., Marchner, H., Wendel, A., Lennernäs, H., & Bengtsson, U. H. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10386 · Cited by 158
Drug prototypes and their exploitation
(1997) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(97)84366-8 · Cited by 147
Potential Drugs and Nondrugs: Prediction and Identification of Important Structural Features
Wagener, M., & van Geerestein, V. J. (2000) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci990266t · Cited by 138
Virtual Screening in Lead Discovery: A Viewpoint
Oprea, T. I. (2002) · Molecules · doi:10.3390/70100051 · Cited by 133
Self-citationImproving the Odds in Discriminating “Drug-like” from “Non Drug-like” Compounds
Frimurer, T. M., Bywater, R. P., Nærum, L., Nørskov‐Lauritsen, L., & Brunak, S. (2000) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci0003810 · Cited by 129
Descriptors, Physical Properties, and Drug-Likeness
Brüstle, M., Beck, B., Schindler, T., King, W., Mitchell, T. J., & Clark, T. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011027b · Cited by 121
Structure-based screening of low-affinity compounds
Carr, R. A. E., & Jhoti, H. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02245-6 · Cited by 112
Predicting therapeutic value in the lead optimization phase of drug discovery
Kenakin, T. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1110 · Cited by 106
Molecular recognition: the fragment approach in lead generation
Fattori, D. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)03007-1 · Cited by 82
(Research Papers) Design of a Compound Screening Collection for use in High Throughput Screening
Harper, G., Pickett, S. T. A., & Green, D. V. S. (2004) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620704772884832 · Cited by 77
Innovation deficit revisited: reflections on the productivity of pharmaceutical R&D
Drews, J. (1998) · Drug Discovery Today · doi:10.1016/s1359-6446(98)01252-5 · Cited by 55
Chemoinformatics and the Quest for Leads in Drug Discovery
Oprea, T. I. (2003) · Wiley eBooks · doi:10.1002/9783527618279.ch44b · Cited by 18
Self-citationCompound Selection for Virtual Screening
Oprea, T. I., Bologa, C., & Olah, M. (2005) · Drug discovery series · doi:10.1201/9781420028775.pt2 · Cited by 13
Self-citationCombinatorics of Small Molecular Structures
Weininger, D. (1998) · Encyclopedia of Computational Chemistry · doi:10.1002/0470845015.cna014m · Cited by 8
The art and practice of structure-based drug design: A molecular modeling perspective
(1996) · doi:10.1002/(sici)1098-1128(199601)16:1<3::aid-med1>3.0.co;2-6
Cited by
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
Combining docking and molecular dynamic simulations in drug design
Alonso, H., Bliznyuk, A. A., & Gready, J. E. (2006) · Medicinal Research Reviews · doi:10.1002/med.20067 · Cited by 759
Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases
Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., & Wyatt, P. G. (2008) · ChemMedChem · doi:10.1002/cmdc.200700139 · Cited by 709
Metadata
- Authors
- Hann, M. M., & Oprea, T. I.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2004-06
- Volume
- 8
- Issue
- 3
- Pages
- 255-263
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2151028167
- Cited by
- 515
- References
- 42
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.